NEUROCRINE BIOSCIENCES INC Debt Securities, Available-for-sale, Noncurrent
NEUROCRINE BIOSCIENCES INC (NBIX) had Debt Securities, Available-for-sale, Noncurrent of $91.90 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent · last filed 2026-07-31
- 2026-06-30: Debt Securities, Available-for-sale, Noncurrent $91.90M.
- 2026-03-31: Debt Securities, Available-for-sale, Noncurrent $1.33B.
- 2025-12-31: Debt Securities, Available-for-sale, Noncurrent $1.06B.
- 2025-09-30: Debt Securities, Available-for-sale, Noncurrent $998.50M.
| Period end | Debt Securities, Available-for-sale, Noncurrent |
|---|---|
| 2026-06-30 | $91.90M 10-Q · filed 2026-07-31 |
| 2026-03-31 | $1.33B 10-Q · filed 2026-05-05 |
| 2025-12-31 | $1.06B 10-Q · filed 2026-07-31 |
| 2025-09-30 | $998.50M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $873.80M 10-Q · filed 2025-07-30 |
| 2025-03-31 | $815.30M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $739.50M 10-K · filed 2026-02-11 |
| 2024-09-30 | $643.90M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $637.80M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $700.40M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $687.50M 10-K · filed 2025-02-10 |
| 2023-09-30 | $454.70M 10-Q · filed 2023-10-31 |
| 2023-06-30 | $342.60M 10-Q · filed 2023-08-01 |
| 2023-03-31 | $244.60M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $299.40M 10-K · filed 2024-02-09 |
| 2022-09-30 | $362.60M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $405.20M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $541.00M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $560.70M 10-Q · filed 2022-11-01 |
| 2021-09-30 | $513.70M 10-Q · filed 2021-11-01 |
| 2021-06-30 | $337.80M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $249.60M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $227.10M 10-Q · filed 2021-11-01 |
| 2020-09-30 | $181.40M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $195.20M 10-Q · filed 2020-08-03 |
| 2020-03-31 | $235.90M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $299.70M 10-Q · filed 2020-11-09 |
| 2018-12-31 | $216.03M 10-K · filed 2019-02-08 |
| 2017-12-31 | $247.36M 10-K · filed 2019-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |